August 6th, 2003

William Morton

I am writing on behalf of the pig tailed macaque # A98056-f. I recently found out about her and that you have her at your laboratory. I'd like to know if she is still alive, is she caged alone and about the status of her overall health if she is still alive. I would like to ask that you retire this monkey. I firmly believe all animals, including this one, should have rights. I believe just because an animal can't communicate and negotiate its needs to humans that this should not deem them to a fate of isolation from their family groups and from contact with some part of their natural world. Animals are no different from another life form that cannot protect its rights--the human child. I am willing to be the voice for the pig-tailed macaque A98056-f that I am writing you about.

I know research saves human lives, but just as it would be unethical to perform such research on a human who did not volunteer, I believe it is unethical to do this also to an animal. If animals did not feel pain, did not suffer, did not react to isolation and environmental deprivation, I would perhaps feel different. I don't believe in saving one being at the expense of the torture of another. Taking a being from it's family, stripping it of dignity and stimulation is torture no matter if this is a person in a prisoner of war camp or a macaque monkey # A98056-f. Please, although having compassion may jeopardize your research, it is the humane and right thing to do. Imagine if someone did research on your pet or family member. It is only different because you have attachment to those things, but not because the animal you are researcher doesn't feel pain. I am not a fundamentalist animal lover. I am an art therapy teacher who lives in Bellingham WA, who works with abused kids who have also suffered under people who did not protect their rights. I value freedom for anyone who doesn't have a voice or a choice. Thank-you. Please retire this monkey. I would like a response to my petition for this release.

Amanda Tysowski

Amanda Tysowski
[redacted]

August 6, 2003

William Morton
Washington Regional Primate Research Center
I-421 Health Sciences Box 357330
Seattle, WA 98195

,
Dear William Morton,

Pursuant to the Federal Freedom of Information Act, 5 U.S.C. 552, I request copies of documents containing the following information: all laboratory reports, protocols, daily care logs, veterinary reports, photographs, videotapes, and any and all other records referring to the pig-tailed macaque A98056-f (07-dec-93.) that is in your facility.

In order to help to determine my status for purposes of determining the applicability of any fees, you should know that I am an individual seeking information for personal use and not for a commercial use. However, I request a waiver of all fees for this request. Disclosure of the requested information to me is in the public interest because it is likely to contribute significantly to public understanding of the operations or activities of the government and is not primarily in my commercial interest.

I will share this information with the Primate Freedom Project (PFP). PFP is a tax-exempt nonprofit public interest organization. PFP actively informs the public about the use of primates in federally funded biomedical research. Through publications, commentary to the press, sponsorship of educational programs and events, and the development of an institutional expertise regarding primate experimentation, PFP has become very involved in raising public awareness concerning this issue.

The use of live animals in research has historically been a matter of wide public interest. The requested documents will illuminate in a clear and direct way the operations and activities of WRPRC pertaining to its use of primates as biomedical test subjects. As such, release of these documents will significantly contribute to public understanding and oversight of this facility's operations, particularly regarding the quality and efficacy of this facility's activities in this area.

PFP will analyze the information presented in the released documents and together with their affiliated experts, including veterinarians and medical doctors, will produce a report as part of their ongoing review of federally supported primate research. The report and any photographs will be published on PFP web sites as well as disseminated to the media as a component of the active involvement in informing the public on this issue. Portions will also be included in printed brochures distributed free to the public as part of an educational campaign. Any suitable video will be aired on community access television networks and shown at public events. These materials will not be used for commercial purposes or gain.

This request is not meant to be exclusive of any other records which, though not specifically requested, would have a reasonable relationship to the subject matter of this request.

In the event that access to any of the requested records is denied, please note that the FOIA provides that if portions of a requested file are exempted from release, the remainder must still be released. I therefore request that I be provided with all non-exempt portions which are reasonably segregable. I further request that you describe the deleted material in detail and specify the statutory basis for the denial as well as your reasons for believing that the alleged statutory justification applies in this instance. Please separately state your reasons for not invoking your discretionary powers to release the requested documents in the public interest. Such statements will be helpful in deciding whether to appeal an adverse determination, and in formulating arguments in case an appeal is taken. This written justification might also help to avoid litigation. I reserve my right to appeal the withholding or deletion of any information and expect that you will list the office and address where such an appeal can be sent.

I anticipate, however, that you will make the requested materials available within the statutorily prescribed period. I also request that you waive any applicable fees since disclosure meets the statutory standard for waiver of fees in that it is clearly "in the public interest because furnishing the information can be considered as primarily benefiting the general public," 5 U.S.C. § 552(a)(4)(A). In this regard, I reiterate that I have no intention of using the information disclosed for financial gain. If for some reason the fee waiver request is denied, while reserving my right to appeal such a decision, I am willing to pay $10 to cover costs of document search and duplication. If you estimate that the fees will exceed this limit, please inform me first.

Thank you for your assistance. I look forward to your reply within 20 business days as required. Failure to respond in a timely manner shall be viewed as a denial of this request and the requester may immediately file an administrative appeal. If you have any questions, please contact me by email or phone.

Sincerely,

Amanda Tysowski

UNIVERSITY OF WASHINGTON
Office of Public Records and Open Public Meetings
4014 University Way NE
Seattle, WA 98105-6203
UW Internal Mail: Box 355502

Prepared for release on:
Tuesday, September 16, 2003

Amanda Tysowski
[redacted]

Dear Ms. Tysowski:

The following is provided in response to public records request #03-8985 in which you request photocopies of documents relating to primate A98056-f.

Upon review, the Public Records Office has found certain items exempt from inspection and copying and has made the appropriate **redactions** per the following Public Disclosure Law provision(s):

Staff Contact Information
Incidents of harassment against University personnel involved with the use of animals in University research are increasing in frequency and intensity and have extended to the homes and personal property of University employees. Therefore, pursuant to the "other statute" exemption provided in RCW 42.17.260(1), the University has redacted the names and personal information of individuals involved with animal research at the University. The University relies on RCW 4.24.580, which is an anti-harassment statute specifically intended to protect individuals employed at research, educational, or agricultural production facilities where animals are used for research, educational, or agricultural purposes, and on the case of Progressive Animal Welfare Society v. University of Washington, 125 Wn.2d 243, 263-264 (1994).

Enclosed are the requested documents. Our office has waived the associated copying costs for this 8 page release.

This concludes the University of Washington's response to your request as provided by the Public Disclosure Laws of Washington State.

Sincerely,

E A Saunders

E. A. Saunders
Director

Office Number: (206) 543-9180
Email: pubrec@u.washington.edu

EAS/jr

Master History Report Printed on 4-Sep-2003 for user MARGARET

A98056 M. nemestrina Female
Sex mods: Ovaries &/or uterus removed
Birth date: 07-DEC-93
Entry date: 02-MAY-98
Departure date: 21-FEB-01
Disposition: Euthanasia, experimental
Inbreeding coefficient: .000
Inbreeding history: .000 due to dam: .000 due to sire: .000
Breeding index: 0 Generation index: .000
*** No Case summary available ***
Place of origin: INDONESIA
Vendor: PT. Wanara Satwaloka
Age estimated: 5.00 years on 03-AUG-98 by dental examination
Age at departure on 21-FEB-01 7.20 years (2633 days)
Previous identification: 1097
Remarks: Previous weights before 8/3/98 are 17% higher

*** No gestational information available ***

First weight: 08-MAY-98 0 9.200 Kg.

*** Full Virus Test Summary ***

Virus	Target	R	Method	Date	Lab
3214 CHV-1 (B virus), Cercopith	antibody	+	Elisa Test	03-MAR-99	UW SeaDL
3214 CHV-1 (B virus), Cercopith	antibody	+	Elisa Test	05-MAY-99	UW SeaDL
3214 CHV-1 (B virus), Cercopith	antibody	+	Elisa Test	08-JUL-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	19-MAY-98	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	19-MAY-98	UW SeaDL
3903 SRV-2 (Type D / Washington	virus	-	Raji Cell Culture	19-MAY-98	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	30-JUN-98	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	30-JUN-98	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	02-SEP-98	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	02-SEP-98	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	16-DEC-98	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	16-DEC-98	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	03-MAR-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	03-MAR-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	05-MAY-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	I	Elisa Test	05-MAY-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	I	Immunoblot	05-MAY-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	21-JUN-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	28-JUN-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	28-JUN-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	08-JUL-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Immunoblot	08-JUL-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	08-JUL-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	03-AUG-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	03-AUG-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	I	Elisa Test	13-SEP-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	I	Immunoblot	13-SEP-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	13-SEP-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	14-OCT-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	14-OCT-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Immunoblot	14-OCT-99	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	20-DEC-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	20-DEC-99	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	10-JUL-00	AM Thoul
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	10-JUL-00	AM Thoul
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	27-SEP-00	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Immunoblot	27-SEP-00	UW SeaDL
3903 SRV-2 (Type D / Washington	viral DNA	-	PCR (Polymerase Cha	28-SEP-00	UW SeaDL
3903 SRV-2 (Type D / Washington	antibody	-	Elisa Test	28-SEP-00	UW SeaDL

```
3903 SRV-2 (Type D / Washington antibody     - Immunoblot          28-SEP-00 UW SeaDL
3904 STLV-I                    antibody     + Elisa Test          20-DEC-99 AM Thoul
3904 STLV-I                    antibody     + Immunoblot          20-DEC-99 AM Thoul
3904 STLV-I                    antibody     + Elisa Test          10-JUL-00 AM Thoul
3904 STLV-I                    antibody     + Elisa Test          28-SEP-00 UW SeaDL
```

*** Moves *** (All 16 Records)

Date	Seq	Room	Cage	Type-housing	Reason
02-MAY-98	0	TRUCK		single animal cage	Hold for shipment
03-MAY-98	0	I089U		single animal cage	quarantine
04-AUG-98	0	I719		group (more than 2)	permanent housing
14-MAY-99	0	I728	5	single animal cage	clinical treatment
15-JUL-99	0	I728	6	single animal cage	Census correction
14-OCT-99	0	I728	6	dam-infant pair in ca	permanent housing
15-OCT-99	0	I728	2	single animal cage	permanent housing
28-MAR-00	0	I031	2	single animal cage	permanent housing
15-APR-00	0	I734	2	single animal cage	permanent housing
30-MAY-00	0	I035	2	single animal cage	permanent housing
11-AUG-00	0	I053	2	single animal cage	Census correction
30-AUG-00	0	I035	3	single animal cage	permanent housing
12-OCT-00	0	I363	17	single animal cage	permanent housing
13-OCT-00	0	I363	23	single animal cage	permanent housing
08-NOV-00	0	I463	3	single animal cage	permanent housing
21-FEB-01	20	DEAD			

*** Weights *** (All 26 Records)

Date	Seq	Weight
08-MAY-98	0	9.200 Kg
19-MAY-98	0	9.500 Kg
03-JUN-98	0	9.580 Kg
16-JUN-98	0	9.580 Kg
30-JUN-98	0	9.400 Kg
28-JUL-98	0	9.180 Kg
03-AUG-98	0	5.300 Kg
02-SEP-98	0	6.000 Kg
14-OCT-98	0	5.600 Kg
16-DEC-98	0	7.400 Kg
22-DEC-98	0	7.400 Kg
11-FEB-99	0	9.000 Kg
17-FEB-99	0	9.000 Kg
03-MAR-99	0	7.600 Kg
05-MAY-99	0	7.200 Kg
28-JUN-99	0	7.200 Kg
08-JUL-99	0	7.200 Kg
07-OCT-99	0	9.200 Kg
15-OCT-99	0	8.400 Kg
20-DEC-99	0	8.200 Kg
10-JUL-00	0	9.000 Kg
28-SEP-00	0	9.800 Kg
31-OCT-00	0	9.800 Kg
27-NOV-00	0	9.500 Kg
20-DEC-00	0	10.400 Kg
08-FEB-01	0	10.000 Kg

*** Tb Tests *** (All 12 Records)

Date	Seq	Where	Ketamine	Atropine	Other-drug	R24	R48	R72	T
08-MAY-98	0	right lid				2	1	1	m
19-MAY-98	0	left lid				2	1	1	m
03-JUN-98	0	right lid				2	2	1	m
16-JUN-98	0	left lid				2	2	2	m

```
30-JUN-98   0 right lid                                    2   1   1 m
14-JUL-98   0 left lid                                     2   2   1 m
28-JUL-98   0 right lid                                    2   1   1 m
16-DEC-98   0 right lid                                    2   2   2 m
28-JUN-99   0 left lid                                     2   1   1 m
20-DEC-99   0 right lid                                    2   1   1 m
10-JUL-00   0 left lid                                     2   2   2 m
20-DEC-00   0 right lid                                    1   1   1 m
```

*** Project Records *** (All 6 Assignments)

Assigned	Returned	Investigator	Pg	Pj	Use	Acc	Expires	Title
02-MAY-98	03-AUG-98	Quarantine	57	01	No Biologic Change	2511-43	05-SEP-04	Quarantine
04-AUG-98	31-MAY-00	Breeding	51	06	No Biologic Change	2511-43	05-SEP-04	Breeding/Reserve Virus-Free
01-JUN-00	13-JUL-00	Research	53	01	No Biologic Change	2511-43	05-SEP-04	Research/Reserve
14-JUL-00	10-SEP-00	[redacted]	08	01	Screening	2195-18	19-SEP-04	STD Prevention- Primate Unit
11-SEP-00	13-DEC-00	[redacted]	06	01	Permanent Biologic Change	2195-10	22-SEP-02	Immunopathogenesis of Experimental Chlamydia Salpingitis
14-DEC-00		Tissue Program	55	01	Terminal	2511-08	13-NOV-03	Tissue Banking and Distribution Program

*** Breeding Records *** (All 5 Records)

Seq	Sire (TuID)	Mated	Separ.	K	Tested	T	R	Conc.	Term.	TC	TR	Infant(TuID)
10	J90153				02-SEP-98	U	N					
20	J90153				14-OCT-98	U	P	05-SEP-98	23-FEB-99	E	NV	K99052
30	J90153				05-MAY-99	U	N					
40	J90153				10-JUN-99	U	P	21-APR-99	14-OCT-99	K	NV	K99294
50	J90153				09-DEC-99	U	N					

*** Blood Draws *** (All 6 Records)

Date	Site	Reason	What Drawn	Where Drawn	Amount	By	SB	Investigator	Pg	Pj
14-OCT-98	Colony	Diagnostic	Blood	Rt. Femoral	3.0	KE				
	Comment: SRV									
28-JUN-99	Colony	Diagnostic	Blood	Rt. Femoral	2.5	KE				
	Comment: SRV									
10-JUL-00	Colony	Diagnostic	Blood		2.5					
	Comment: with TB test									
28-SEP-00	Colony	Diagnostic	Blood	Rt. Femoral	4.5	PETER		[redacted]	06	01
26-DEC-00	Colony	Research	Blood	Rt. Femoral	14.0	EN			01	01
08-FEB-01	Colony	Research	Blood	Rt. Femoral	3.0	EN			44	27

*** Hematologies *** (All 1 Records)

OPTIONS: Differential data are reported here as absolute counts.

Animal	Tested	HEMO	PCV	RBC	MCH	MCV	MCHC	IM	RET	ORC	PL	ESR	WBC	NEUTR	BAND	LYMPH	MONOC	EOSIN	BASOP	PLASM	ATYPL	GRANU	OTHER	ME	MY	PC	PB	AN	PI	MA	MI	HY	PL	BS	LE
A98056	08-MAY-98	12.5	40.0	5.61	22.2	71.0	31.1				522		9.5	4750		3705	665	285	95																

*** No Blood Parasite Records ***

*** No Blood Chemistry Records ***

*** No CSF Test Records ***

*** No Urinalysis Test Records ***

Master History Report Printed on 4-Sep-2003 for user MARGARET

*** Snomed Reports *** (All IQs; All 20 Records)
(Please note that some test results are available
only through MICRO and VIRUS.)
Observation on 08-MAY-98:
PHYSICAL EXAMINATION performed.
Ivermectin.
Praziquantel (Droncit).
LEFT HAND.
FRACTURE of FIFTH FINGER.
NEEDS TEETH CLEANED.

Clinical Procedure on 03-JUN-98:
Ivermectin.
Praziquantel (Droncit).

Clinical Procedure on 16-JUN-98:
Ivermectin.

Clinical Procedure on 30-JUN-98:
Ivermectin.

Clinical Procedure on 14-JUL-98:
Ivermectin.

Clinical Procedure on 28-JUL-98:
Ivermectin.

Observation on 03-AUG-98:
Dental Examination For Aging performed.

Clinical Procedure on 14-OCT-98:
ULTRASOUND IMAGERY PROCEDURE performed.

Clinical Procedure on 16-DEC-98:
Ivermectin.

Observation on 11-FEB-99:
PHYSICAL EXAMINATION performed.
PREPARTUM.

Observation on 03-MAR-99:
POSTPARTUM EXAM AND OBSERVATION OF DAM AND INFANT performed.

Clinical Procedure from 28-JUN-99 to 28-JUN-99:
Ivermectin.
Dental Prophylaxis, Cleaning performed.

Clinical Procedure on 07-OCT-99:
PREPARTUM EXAM performed.

Clinical Disorder from 15-OCT-99 to 25-OCT-99:
PLACENTA, ADHERENT.
For which was done: ORAL ADMINISTRATION performed. Cephalexin (Keflex).

Clinical Procedure on 20-DEC-99:
Dental Prophylaxis, Cleaning performed.
DE-WORM performed. Ivermectin.

Clinical Procedure from 10-JUL-00 to 10-JUL-00:
with TB test.
Dental Prophylaxis, Cleaning performed.
Additionally, DE-WORM performed. Ivermectin.
PHYSICAL EXAMINATION, COMPLETE performed.

Experimental Surgery from 28-SEP-00 to 28-SEP-00:
LEFT FALLOPIAN TUBE. LAPAROTOMY performed.
The above is followed by FIMBRIA OF FALLOPIAN TUBE. SPECIMEN COLLECTION performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.

Experimental Surgery from 31-OCT-00 to 31-OCT-00:
RIGHT LOWER QUADRANT OF ABDOMEN. LAPAROTOMY performed.
The above resulted in FIMBRIA OF FALLOPIAN TUBE. SPECIMEN COLLECTION performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.

Experimental Surgery from 27-NOV-00 to 27-NOV-00:
UTERUS AND FALLOPIAN TUBES, CS. INCISION AND REMOVAL performed.
CERVIX UTERI. INCISION AND REMOVAL performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.

Clinical Procedure from 20-DEC-00 to 20-DEC-00:
with TB test.
Dental Prophylaxis, Cleaning performed.
Additionally, DE-WORM performed. Ivermectin.
PHYSICAL EXAMINATION, COMPLETE performed.

*** No Microbiology Reports ***

*** Surgery Reports *** (All 3 Records)
28-SEP-00: Minor Experimental Surgery Abdominal Seattle Colony.
LEFT FALLOPIAN TUBE. LAPAROTOMY performed.
The above is followed by FIMBRIA OF FALLOPIAN TUBE. SPECIMEN COLLECTION performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.
General anesthesia: Isoflurane
Route: Cuffed Intratracheal Tube
Fluid administration: Normal Saline
Investigator: [redacted] Program: 6 Project: 1
Surgeon: [redacted] P.C. Staff
Coded-by: [redacted]

31-OCT-00: Major Experimental Surgery Laparoscopy Seattle Colony.
RIGHT LOWER QUADRANT OF ABDOMEN. LAPAROTOMY performed.
The above resulted in FIMBRIA OF FALLOPIAN TUBE. SPECIMEN COLLECTION performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.
General anesthesia: Sevoflurane
Route: Cuffed Intratracheal Tube
Fluid administration: Lactated Ringer's Solution
Investigator: [redacted] Program: 6 Project: 1
Surgeon: [redacted] Investigator Staff
Coded-by: [redacted]

27-NOV-00: Major Experimental Surgery Abdominal Seattle Colony.
UTERUS AND FALLOPIAN TUBES, CS. INCISION AND REMOVAL performed.

CERVIX UTERI. INCISION AND REMOVAL performed.
For which was done: ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed.
Ketoprofen (Ketofen).
ADMINISTRATION OF MEDICATION, INTRAMUSCULAR performed. Oxymorphone.
General anesthesia: Isoflurane
Route: Cuffed Intratracheal Tube
Fluid administration: Lactated Ringer's Solution
Investigator: [redacted] Program: 6 Project: 1
Surgeon: [redacted] P.C. Staff
Coded-by: [redacted]

***** End of Report for A98056 *****

Protocol: STD Prevention – Primate Unit

The Sexually Transmitted Disease Prevention–Primate Unit (STDP-PU) contract has been established as a means to comparatively assess topical microbicide products vis-à-vis safety to cervical/vaginal tissues after repeated use, and efficacy in preventing cervical chlamydial infection.

The contract is designed to assess first, effects that a formulated microbicide product has on the surface tissues and microenvironment of the cervix and vagina (modified colposcopy, cervical gram stain, pH, vaginal flora), thirty minutes and 24 hours after each application when applied daily for four days. Cervical and vaginal biopsies will be collected 24 hours after the final application to assess the cellular immune response induced by repeated use. This experiment also tests for tissue and flora recovery within one week following final application.

After a product has been shown not to induce deleterious outcome after repeated use, it will be assessed for its ability to prevent chlamydial infection of the cervix. In this experiment, a single dose of the formulated microbicide product is applied to each of six animals, followed (at thirty minutes) by a cervical challenge with *Chlamydia trachomatis*. Detection of viable chlamydial organisms and DNA, as well as serum antibody to chlamydia will be attempted for seven weeks post inoculation. In addition, a cervical biopsy will be collected at seven days post-inoculation, which will be assessed for presence of chlamydial antigen in the cervical tissue.

Protocol: Immunopathogenesis of Experimental Chlamydial Salpingitis

This study was designed to investigate several factors of the immune response to cervical chlamydial challenges, including genetic predisposition to progression of disease, specific immune responses (cytokine activity) to chlamydial infection, and identification of chlamydial antigen in tissues. Effectiveness of treatment was also being assessed in doxycycline vs. azithromycin treated animals, for lower and upper reproductive tract chlamydial infections. MHC testing has been performed on all monkeys enrolled in this project. Studies specific to cytokine expression and immune responses to upper vs. lower tract disease were conducted. All animals were randomly assigned to treatment groups before initiation of the study. The placebo treatment group was larger so that untreated animals can be followed for progression of disease studies. Though animal work has been completed, publications for May 2002 through April 2003 continue.